Targeting Interleukin 13 for the Treatment of Atopic Dermatitis [PDF]
Pharmaceutics, 2023 Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj +3 more sources
Interleukin-13 (IL-13)-A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis. [PDF]
Int J Mol Sci, 2023 The liver, as a central metabolic organ, is systemically linked to metabolic–inflammatory diseases. In the pathogenesis of the metabolic syndrome, inflammatory and metabolic interactions between the intestine, liver, and adipose tissue lead to the ...
Roeb E.
europepmc +2 more sources
Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. [PDF]
Dermatol Ther (Heidelb), 2023 IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13.
Okragly AJ +6 more
europepmc +2 more sources
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. [PDF]
Front Med (Lausanne), 2023 Recent evidence suggests that interleukin (IL)-13 is a crucial cytokine involved in the pathogenesis of atopic dermatitis (AD). It is a central driver of type-2 T-helper inflammation and is overexpressed in lesional skin of AD patients.
Napolitano M +4 more
europepmc +2 more sources
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid [PDF]
Annals of Medicine, 2023 Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230.
Fangyuan Chen +4 more
doaj +2 more sources
An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Human Skin Equivalent Model by a Skin-On-A-Chip [PDF]
International Journal of Molecular Sciences, 2022 Currently, the mechanism of progression of atopic dermatitis (AD) is not well understood because there is no physiologically appropriate disease model in terms of disease complexity and multifactoriality. Type 2 inflammation, mediated by interleukin (IL)-
Kyung‐Hee Kim +2 more
openalex +2 more sources
Interleukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection. [PDF]
Nat Commun, 2023 Immune system molecules are expressed by neurons, yet their functions are often unknown. We have identified IL-13 and its receptor IL-13Ra1 as neuronal, synaptic proteins in mouse, rat, and human brains, whose engagement upregulates the phosphorylation ...
Li S +21 more
europepmc +2 more sources
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. [PDF]
Front ImmunolChronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly a type 2 inflammatory disease associated with type 2 (T2) cell responses and epithelial barrier, mucociliary, and olfactory dysfunction.
Bachert C +8 more
europepmc +2 more sources
Interleukin 13 Promotes Maturation and Proliferation in Metaplastic GastroidsSummary [PDF]
Cellular and Molecular Gastroenterology and HepatologyBackground & Aims: Type 2 innate lymphoid cells (ILC2s) and interleukin-13 (IL-13) promote the onset of spasmolytic polypeptide-expressing metaplasia (SPEM) cells. However, little is known about molecular effects of IL-13 in SPEM cells. We now sought
Ela W. Contreras-Panta +8 more
doaj +2 more sources
Evaluation of the levels of interleukins IL-4, IL-13, IL-5, IL-10 and IL-33 in atopic dermatitis patients with and without dupilumab therapy [PDF]
Frontiers in ImmunologyBackgroundInterleukins IL-4, Il-5, IL-10, IL-13 and IL-33 play an important role in atopic dermatitis patients. The aim of our study is to address several knowledge gaps in the understanding of interleukin dynamics in atopic dermatitis patients and the ...
Jarmila Čelakovská +3 more
doaj +2 more sources